反応式
[CH3:1][O:2][CH2:3][CH2:4][O:5][C:6]1[CH:11]=[C:10]2[C:12]([NH:16][C:17]3[CH:22]=[C:21]([C:23]#[CH:24])[CH:20]=[CH:19][CH:18]=3)=[N:13][CH:14]=[N:15][C:9]2=[CH:8][C:7]=1[O:25][CH2:26][CH2:27][O:28][CH3:29].C(OCC)=O.[ClH:35]>C(O)(C)C>[CH3:1][O:2][CH2:3][CH2:4][O:5][C:6]1[CH:11]=[C:10]2[C:12]([NH:16][C:17]3[CH:18]=[CH:19][CH:20]=[C:21]([C:23]#[CH:24])[CH:22]=3)=[N:13][CH:14]=[N:15][C:9]2=[CH:8][C:7]=1[O:25][CH2:26][CH2:27][O:28][CH3:29].[ClH:35]参加物
5
反応条件
- 温度
- 5 °C
実験手順
10.0 g crystal form IV of erlotinib base was added to 200 ml ethyl formate, heated to 0-10° C., 6.4 g isopropanol saturated with HCl gas was added dropwise, after dripping, stirred for 30 minutes while maintaining the temperature, stirred for 1 hour at 0-15° C. before filtration, dried at 50° C. to obtain 10.2 g sample of crystal form A. The yield was 93.6% and the purity was 99.7% (by HPLC).
後処理
- temperaturewhile maintaining the temperature
- stirringstirred for 1 hour at 0-15° C. before filtration
- customdried at 50° C.
- customto obtain 10.2 g sample of crystal form A
出典と根拠
- ORDレコード
- ord-aecce3c5959c49b5b418011801015501
- 出典データセット
- uspto-grants-2014_02
- 特許番号
- US08653264B2
関連ノート
読み込み中…